Highnoon Laboratories Limited (PSX:HINOON)

Market Cap	48.45B
Revenue (ttm)	24.63B
Net Income (ttm)	3.39B
Shares Out	52.98M
EPS (ttm)	63.95
PE Ratio	14.30
Forward PE	n/a
Dividend	40.00 (4.30%)
Ex-Dividend Date	Apr 18, 2025

Volume	20,383
Average Volume	94,075
Open	915.00
Previous Close	929.84
Day's Range	900.99 - 925.00
52-Week Range	535.00 - 1,000.00
Beta	0.14
RSI	47.55
Earnings Date	Apr 9, 2025

About Highnoon Laboratories

Highnoon Laboratories Limited, together with its subsidiaries, manufactures, imports, sells, exports, and markets pharmaceutical and allied consumer products. It offers products in various therapeutic areas, including allergy, anti-infective, cardiology, gastroenterology, metabolic, musculoskeletal, obstetrics and gynaecology, paediatrics, respiratory, and urology; and generic products under various brands. The company serves Pakistan, Afghanistan, the United Arab Emirates, France, Kenya, Iraq, Cambodia, Tanzania, and internationally. Highnoon ...

• Industry: Pharmaceuticals
• Sector: Healthcare
• Founded: 1984
• Employees: 2,376
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: HINOON

Financial Performance

In 2024, Highnoon Laboratories's revenue was 24.63 billion, an increase of 24.60% compared to the previous year's 19.77 billion. Earnings were 3.39 billion, an increase of 38.44%.